Is Samrat Pharma overvalued or undervalued?

As of 14 August 2025, Samrat Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived market value. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 20.54, an EV to EBITDA of 12.55, and a PEG Ratio of 0.62, which suggests a reasonable growth expectation relative to its earnings.
In comparison to its peers, Samrat Pharma's valuation stands out against Sun Pharma, which is considered expensive with a PE Ratio of 34.24, and Dr. Reddy's Labs, which is attractive at a PE of 18.48. The current price of 319.70 reflects a significant decline from its 52-week high of 646.00, and the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -16.32% compared to the Sensex's 3.15%. Overall, while the company is fairly valued, the recent performance trends may warrant caution for potential investors.